Dow Jones Industrial Average ETF vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Dow Jones Industrial Average ETF trades at $512.44 (market cap $45.20B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.22 (market cap $2.27B). The key difference: Dow Jones Industrial Average ETF is far larger — about 19.9× SELLAS Life Sciences Group Inc. Common Stock's market cap, and SELLAS Life Sciences Group Inc. Common Stock is more actively traded (4,179,659 versus 4,095,368). Which is the better fit depends on your goals.
| DIA | SLS | |
|---|---|---|
Market Cap | $45.20B | $2.27B |
Volume | 4,095,368 | 4,179,659 |
52-Week High | $542.79 | $15.46 |
52-Week Low | $451.37 | $1.39 |
Typical Hold Time | 103 Days | — |
Sector | — | Health |
Enterprise Value | — | $2.14B |
Signals from Pluang's Aura AI — not financial advice
DIA (SPDR Dow Jones Industrial Average ETF Trust) trades at $511.02, down 0.68% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF provides exposure to the 30 blue-chip Dow Jones Industrial Average components, offering diversified large-cap value. Recent dividend distributions in 2026 provide income, while broader market sentiment reflects caution amid economic uncertainty and Federal Reserve policy focus.
The outlook for DIA hinges on the performance of the Dow 30 constituents, with potential upside from strong corporate earnings but risks from high bond yields and market volatility. As a passive ETF, its value tracks the index, making macroeconomic trends and interest rate expectations key drivers. Current technical weakness near support at $509 suggests near-term pressure, though long-term investors may find stability in its blue-chip holdings.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →